Trials / Terminated
TerminatedNCT06421311
Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France
Ambispective Observational Study of Muscle Invasive Urothelial Carcinoma Patients Treated With Adjuvant Nivolumab in France
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 176 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will estimate the real-world effectiveness of adjuvant nivolumab therapy in adult participants with muscle invasive urothelial carcinoma (MIUC) in France.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nivolumab | According to approved product label (France) |
Timeline
- Start date
- 2024-07-30
- Primary completion
- 2025-04-04
- Completion
- 2025-04-04
- First posted
- 2024-05-20
- Last updated
- 2025-06-05
Locations
1 site across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06421311. Inclusion in this directory is not an endorsement.